The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
Open accessAbstract
TIC10 is a small molecule that activates Foxo3a through dual inactivation of Akt and ERK, up-regulates the expression of the TRAIL gene, an endogenous tumor suppressor, and effectively improves the therapeutic properties and utility of TRAIL as an anticancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497 · cited 1×
“The bystander protein production strategy must be used carefully because normal cells must maintain their normal function and the target protein must be nontoxic to the normal cells, as is the case for TRAIL (32).”
BackgroundSafety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
The Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
FOXO transcription factors at the interface between longevity and tumor suppression
Greer, E. L., & Brunet, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209086 · Cited by 1,310
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
Self-citationDisruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011) · Nature Biotechnology · doi:10.1038/nbt.2017 · Cited by 919
IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a
Hu, M. C.-T., Lee, D.-F., Xia, W., Golfman, L. S., Ou-Yang, F., Yang, J.-Y., Zou, Y., Bao, S., Hanada, N., Saso, H., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00302-2 · Cited by 868
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
Yang, J.-Y., Zong, C. S., Xia, W., Yamaguchi, H., Ding, Q., Xie, X., Lang, J.-Y., Lai, C.-C., Chang, C.-J., Huang, W.-C., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1676 · Cited by 697
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2005) · Nature Medicine · doi:10.1038/nm1161 · Cited by 610
FOXO Proteins Regulate Tumor Necrosis Factor-related Apoptosis Inducing Ligand Expression
Modur, V., Nagarajan, R., Evers, B. M., & Milbrandt, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207509200 · Cited by 371
Kau, T. R., Schroeder, F., Ramaswamy, S., Wojciechowski, C. L., Zhao, J. J., Roberts, T. M., Clardy, J., Sellers, W. R., & Silver, P. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00303-9 · Cited by 329
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0950 · Cited by 247
Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210
Menon, L. G., Kelly, K., Yang, H. W., Kim, S.-K., Black, P. M., & Carroll, R. S. (2009) · Stem Cells · doi:10.1002/stem.136 · Cited by 185
Trarbach, T., Moehler, M., Heinemann, V, Köhne, C.-H., Przyborek, M., Schulz, C., Sneller, V, Gallant, G., & Kanzler, S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605507 · Cited by 180
Burns, T. F., & El‐Deiry, W. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103516200 · Cited by 171
Self-citationCamidge, D. R., Herbst, R. S., Gordon, M. S., Eckhardt, S. G., Kurzrock, R., Durbin, B., Ing, J., Tohnya, T. M., Sager, J., Ashkenazi, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1267 · Cited by 169
Greco, F. A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G., & Klein, J. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.011 · Cited by 168
TRAIL receptor signaling and therapeutics
Abdulghani, J., & El‐Deiry, W. S. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.519701 · Cited by 161
Self-citationRequirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy
Wang, S., & El‐Deiry, W. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2435285100 · Cited by 153
Self-citationGhaffari, S., Jagani, Z., Kitidis, C., Lodish, H. F., & Khosravi‐Far, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0731871100 · Cited by 147
Shareef, M. M., Cui, N., Burikhanov, R., Gupta, S., Satishkumar, S., Shajahan, S., Mohiuddin, M., Rangnekar, V. M., & Ahmed, M. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0722 · Cited by 147
Leong, S., Cohen, R. B., Gustafson, D. L., Langer, C. J., Camidge, D. R., Padavic, K., Gore, L., Smith, M., Chow, L. Q. M., von Mehren, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7422 · Cited by 134
Wang, W., Kim, S.-H., & El‐Deiry, W. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604507103 · Cited by 125
Self-citationTNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death
Kuribayashi, K., Krigsfeld, G. S., Wang, W., Xu, J., Mayes, P. A., Dicker, D. T., Wu, G. S., & El‐Deiry, W. S. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.7460 · Cited by 122
Self-citationvan Grevenynghe, J., Cubas, R. A., Noto, A., DaFonseca, S., He, Z., Peretz, Y., Filali-Mouhim, A., Dupuy, F. P., Procopio, F. A., Chomont, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59211 · Cited by 111
Mom, C. H., Verweij, J., Oldenhuis, C. N. A. M., Gietema, J. A., Fox, N. L., Miceli, R. C., Eskens, F. A. L. M., Loos, W. J., de Vries, E. G. E., & Sleijfer, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0996 · Cited by 106
Kim, S., Kim, K., Kwagh, J., Dicker, D. T., Herlyn, M., Rustgi, A. K., Chen, Y., & El‐Deiry, W. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404541200 · Cited by 98
Self-citationRegulation of the human TRAIL gene
Allen, J. E., & El‐Deiry, W. S. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21354 · Cited by 90
Self-citationCornforth, A. N., Davis, J. S., Khanifar, E., Nastiuk, K. L., & Krolewski, J. J. (2008) · Oncogene · doi:10.1038/onc.2008.80 · Cited by 77
Yang, J.-Y., Chang, C.-J., Xia, W., Wang, Y., Wong, K., Engelman, J. A., Du, Y., Andreeff, M., Hortobágyi, G. N., & Hung, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4524 · Cited by 70
Finnberg, N. K., & El‐Deiry, W. S. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.7.1057 · Cited by 65
Self-citationYang, W., Dolloff, N. G., & El‐Deiry, W. S. (2008) · Nature Cell Biology · doi:10.1038/ncb0208-125 · Cited by 57
Self-citationPark, S.-J., Sohn, H., Yoon, J., & Park, S. I. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.05.008 · Cited by 49
Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
Allen, J. E., Ferrini, R., Dicker, D. T., Batzer, G. M., Chen, E., Oltean, D. I., Lin, B., Renshaw, M. W., Kretz-Rommel, A., & El‐Deiry, W. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0366 · Cited by 28
Self-citationTargeting FOXO Kills Two Birds with One Stone
Wang, W., & El‐Deiry, W. S. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.01.011 · Cited by 15
Self-citation
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Self-citationGenetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality
Ishizawa, J., Zarabi, S. F., Davis, R. E., Halgas, O., Nii, T., Jitkova, Y., Zhao, R., St-Germain, J., Heese, L. E., Egan, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.014 · Cited by 349
Metadata
- Authors
- Allen, J. E., Krigsfeld, G., Mayes, P. A., Patel, L., Dicker, D. T., Patel, A. S., Dolloff, N. G., Messaris, E., Scata, K. A., Wang, W., Zhou, J.-Y., Wu, G. S., & El-Deiry, W. S.
- Venue
- Science Translational Medicine
- Published
- 2013-02-06
- Volume
- 5
- Issue
- 171
- Pages
- 171ra17-171ra17
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2162606162
- Cited by
- 342
- References
- 42
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.